Mohammed Anowrul KABIR,Odin Johann NADERER,Irma Marisa GROSSI
申请号：
US16722699
公开号：
US20200138835A1
申请日:
2019.12.20
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Disclosed are formulations comprising brincidofovir. The formulations can be intravenous formulations. The formulations can be used in cases where a subject experiences gastrointestinal issues in response to oral administration of brincidofovir. The formulations can also be used in cases where oral administration of drug is not possible due to underlying conditions or concern around inadequate oral absorption.
